Dosimetry and optimal scan time of [
Dosimetry
NET
PET/CT
[18F]SiTATE
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
17
12
2020
accepted:
04
04
2021
pubmed:
1
5
2021
medline:
21
10
2021
entrez:
30
4
2021
Statut:
ppublish
Résumé
Radiolabelled somatostatin analogues targeting somatostatin receptors (SSR) are well established for combined positron emission tomography/computer tomography (PET/CT) imaging of neuroendocrine tumours (NET). [ Eight NET patients received a [ After 1 h, normal organs showed similar tracer uptake with only negligible changes until 3 h post-injection. In contrast, tracer uptake by tumours increased progressively for almost all types of metastases, thus increasing tumour-to-background ratios over time. Dosimetry resulted in a total effective dose of 0.015 ± 0.004 mSv/MBq. Visual evaluation revealed no clinically relevant discrepancies between later scan times, but image quality was rated highest in 60 and 120 min images. [
Identifiants
pubmed: 33928401
doi: 10.1007/s00259-021-05351-x
pii: 10.1007/s00259-021-05351-x
pmc: PMC8440281
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3571-3581Informations de copyright
© 2021. The Author(s).
Références
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):989-998
pubmed: 29460025
Appl Radiat Isot. 2013 Jun;76:2-13
pubmed: 23522791
Eur J Nucl Med. 2001 Jul;28(7):836-46
pubmed: 11504080
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
EJNMMI Radiopharm Chem. 2020 Jan 29;5(1):4
pubmed: 31997090
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601
pubmed: 28547177
J Nucl Med. 2019 Mar;60(3):299-303
pubmed: 30733314
Bioconjug Chem. 2010 Dec 15;21(12):2289-96
pubmed: 21082773
Pharmaceuticals (Basel). 2020 Mar 03;13(3):
pubmed: 32138377
Eur J Nucl Med Mol Imaging. 2011 May;38(5):940-8
pubmed: 21287170
J Int Bioethique. 2004 Mar;15(1):124-9
pubmed: 15835069
Theranostics. 2019 Feb 14;9(5):1336-1347
pubmed: 30867834
Angew Chem Int Ed Engl. 2006 Sep 11;45(36):6047-50
pubmed: 16888726
J Nucl Med. 2019 Sep;60(9):1266-1269
pubmed: 30850506
J Nucl Med. 2013 Jun;54(6):855-60
pubmed: 23516312
J Nucl Med. 2018 Apr;59(4):625-631
pubmed: 28986512
Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S219-23
pubmed: 10604135
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):677-685
pubmed: 30374529
EJNMMI Res. 2019 Jul 25;9(1):66
pubmed: 31346821
Nucl Med Biol. 2020 Sep-Oct;88-89:86-95
pubmed: 32828007
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):870-880
pubmed: 31492994
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2400-2401
pubmed: 31352578
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):2944-2946
pubmed: 32715336
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):50-6
pubmed: 21932117
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046
pubmed: 32617641
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):204-216
pubmed: 32572559
J Nucl Med. 2013 Oct;54(10):1755-9
pubmed: 23929824
Curr Top Med Chem. 2014;14(7):875-900
pubmed: 24484425
Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1238-50
pubmed: 20411259
EJNMMI Phys. 2016 Dec;3(1):8
pubmed: 27271304
Theranostics. 2018 Nov 29;8(22):6088-6100
pubmed: 30613284
J Nucl Med. 2019 Dec;60(12):1736-1742
pubmed: 31028165
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
J Nucl Med. 2015 Jul;56(7):1100-5
pubmed: 25977461
Neuroendocrinology. 2017 Mar 30;105(3):212-244
pubmed: 28355596